Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Talking it out: study tests if doctor training eases cancer Survivors' transition

NCT ID NCT01483664

Knowledge-focused Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether training doctors in communication skills can help lymphoma patients move from active treatment to survivorship. It involves 314 patients with Hodgkin's or Diffuse Large B-cell Lymphoma. The goal is to see if better conversations with their doctors improve patient outcomes during this challenging transition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
communication skills training
What this could lead to
If successful, this could show that better doctor-patient communication improves the emotional and practical well-being of lymphoma survivors.
What could go wrong
This is an early-stage behavioral study, not a drug trial. Results may not show a clear benefit, and the training may not be widely adopted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

314 people

The number who actually took part.

Start date

Nov 2011

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients: Patients from each site will be recruited from their respective lymphoma services. Physicians: Physicians from each site will be recruited from their respective lymphoma services.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Physicians: * who treat patients with DLBCL and HD as per self report Patients of Physicians: * have a new diagnosis of Hodgkin's or Diffuse Large B-cell Lymphoma as per pathology report or physician assessment in medical record and/or clinical judgment of the treating physician treated with curative intent. For part 1 - have scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment. For part 2 (longitudinal phase): - have new scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment. * be at least 18 years old * speak English well enough, in the judgment of the consenting professional, to be able to understand all aspects of the study, provide informed consent, and be able to complete all study measures. Exclusion Criteria: Physicians: * who do not have adequate patients in their clinical practice to meet the 8 patient enrollment requirement for patients with either DLBCL or HD as per self report Patients of Physicians: * show evidence of cognitive impairment severe enough to preclude giving permission to the study staff, or completing the survey instruments of the study. * as per physician judgment, patient's prognosis and/or co-morbidities make them inappropriate for participation in a survivorship study. For Part 2 ONLY (longitudinal phase): * those who consented to part 1, consult recording, of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B cell lymphoma Hodgkin's lymphoma

Contacts and locations

Locations

  • Maimonides Medical Center

    Brooklyn, New York, 11220, United States

  • Md Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center at Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Cancer Center at Mercy

    Rockville Centre, New York, 11570, United States

  • Memorial Sloan Kettering Cancer Center at Phelps

    Sleepy Hollow, New York, 10591, United States

  • Memorial Sloan Kettering at Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Tampa General Hospital

    Tampa, Florida, 33606, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.